Compare · NVO vs PPBT
NVO vs PPBT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Purple Biotech Ltd. (PPBT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PPBT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 69267.8x PPBT ($2.8M).
- Over the past year, NVO is down 45.0% and PPBT is down 92.4% - NVO leads by 47.3 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for PPBT).
- NVO has more recent analyst coverage (25 ratings vs 0 for PPBT).
- Company
- Novo Nordisk A/S
- Purple Biotech Ltd.
- Price
- $43.27+1.11%
- $2.00-30.92%
- Market cap
- $191.15B
- $2.8M
- 1M return
- -7.93%
- -47.78%
- 1Y return
- -45.04%
- -92.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. Its oncology pipeline includes NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest PPBT
- SEC Form 6-K filed by Purple Biotech Ltd.
- Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
- SEC Form F-3 filed by Purple Biotech Ltd.
- SEC Form 6-K filed by Purple Biotech Ltd.
- Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
- SEC Form 6-K filed by Purple Biotech Ltd.
- Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
- SEC Form 6-K filed by Purple Biotech Ltd.
- Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
- SEC Form 3 filed by new insider Rock Simcha